Literature DB >> 1575581

Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus.

H J Out1, M van Vliet, P G de Groot, R H Derksen.   

Abstract

Fluctuations of lupus anticoagulant activity and anticardiolipin antibody titres were studied in 53 patients with systemic lupus erythematosus (SLE). The median study time was 26 months with a median number of 12 samples. Lupus anticoagulant was measured by the kaolin clotting time (KCT) and dilute Russell viper venom time (dRVVT) assays; anticardiolipin antibodies were assayed by an enzyme linked immunosorbent assay (ELISA). Normal and increased KCTs or dRVVTs were seen during follow up in 13 and 12 patients, respectively. IgG anticardiolipin antibodies changed from negative to positive or positive to negative in 26 patients and IgM anticardiolipin antibodies in 16 patients. Disease activity and treatment with prednisone could account for these fluctuations in the kaolin clotting time (KCT) in 7 of 13 patients and in the dRVVT in 2 of 12 patients. Whole group analysis showed that the KCT, dRVVT, and IgM anticardiolipin antibodies were not associated with disease activity, in contrast with IgG anticardiolipin antibodies. During treatment with prednisone normal KCT and dRVVT results were obtained more easily than normal anticardiolipin antibody levels. It is recommended that lupus patients should not be classified as antiphospholipid antibody positive or negative on the basis of only one sample.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1575581      PMCID: PMC1004660          DOI: 10.1136/ard.51.3.353

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  18 in total

1.  Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study.

Authors:  H J Out; P G de Groot; P Hasselaar; M dan Vliet; R H Derksen
Journal:  Ann Rheum Dis       Date:  1989-12       Impact factor: 19.103

2.  Anticardiolipin response in acute infections.

Authors:  O Vaarala; T Palosuo; M Kleemola; K Aho
Journal:  Clin Immunol Immunopathol       Date:  1986-10

3.  The relationship of anticardiolipin antibodies to disease manifestations in pediatric systemic lupus erythematosus.

Authors:  W J Shergy; D W Kredich; D S Pisetsky
Journal:  J Rheumatol       Date:  1988-09       Impact factor: 4.666

4.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

5.  Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study.

Authors:  E J ter Borg; G Horst; E J Hummel; P C Limburg; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1990-05

6.  Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus.

Authors:  K C Kalunian; J B Peter; H R Middlekauff; J Sayre; D G Ando; M Mangotich; B H Hahn
Journal:  Am J Med       Date:  1988-11       Impact factor: 4.965

7.  Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results.

Authors:  S Loizou; J D McCrea; A C Rudge; R Reynolds; C C Boyle; E N Harris
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

8.  Fetal survival after prednisone suppression of maternal lupus-anticoagulant.

Authors:  W F Lubbe; W S Butler; S J Palmer; G C Liggins
Journal:  Lancet       Date:  1983-06-18       Impact factor: 79.321

9.  Obstetric complications associated with the lupus anticoagulant.

Authors:  D W Branch; J R Scott; N K Kochenour; E Hershgold
Journal:  N Engl J Med       Date:  1985-11-21       Impact factor: 91.245

Review 10.  Lupus anticoagulant: revival of an old phenomenon.

Authors:  R H Derksen; L Kater
Journal:  Clin Exp Rheumatol       Date:  1985 Oct-Dec       Impact factor: 4.473

View more
  7 in total

Review 1.  Treatment of the antiphospholipid syndrome.

Authors:  J C Piette; M Karmochkine; T Papo; L T Du; C Francès; B Wechsler
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

2.  Prevention of behavioral deficits in rats exposed to folate receptor antibodies: implication in autism.

Authors:  A Desai; J M Sequeira; E V Quadros
Journal:  Mol Psychiatry       Date:  2016-09-20       Impact factor: 15.992

3.  Real world experience with antiphospholipid antibody tests: how stable are results over time?

Authors:  D Erkan; W J M Derksen; V Kaplan; L Sammaritano; S S Pierangeli; R Roubey; M D Lockshin
Journal:  Ann Rheum Dis       Date:  2005-02-24       Impact factor: 19.103

4.  Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome?

Authors:  A Ghirardello; A Doria; A Ruffatti; A M Rigoli; P Vesco; A Calligaro; P F Gambari
Journal:  Ann Rheum Dis       Date:  1994-02       Impact factor: 19.103

5.  Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus.

Authors:  Selcan Demir; Jessica Li; Laurence S Magder; Michelle Petri
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

6.  Clinical Application of Revised Laboratory Classification Criteria for Antiphospholipid Antibody Syndrome: Is the Follow-Up Interval of 12 Weeks Instead of 6 Weeks Significantly Useful?

Authors:  Sang Hyuk Park; Seongsoo Jang; Chan-Jeoung Park; Hyun-Sook Chi
Journal:  Biomed Res Int       Date:  2016-08-17       Impact factor: 3.411

7.  High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients.

Authors:  Sahwa Elbagir; Amir I Elshafie; Elnour M Elagib; NasrEldeen A Mohammed; Mawahib Ie Aledrissy; Vivek Anand Manivel; Eleftheria Pertsinidou; Musa Am Nur; Iva Gunnarsson; Elisabet Svenungsson; Johan Rönnelid
Journal:  Lupus       Date:  2020-08-02       Impact factor: 2.911

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.